1292275-52-5

Upstream product

• 1292274-93-1 2-(4-trifluoromethoxy-phenyl)-2-aza-spiro[4.5]decane-1,8-dione 
• 81290-20-2 (trifluoromethyl)trimethylsilane 
• 1489-97-0 ethyl 1,4-dioxaspiro[4.5]decane-8-carboxylate 
• 17159-79-4 ethyl 4-oxocyclohexane-1-carboxylate 
• 1292278-43-3 1-(2-methoxy-ethyl)-4-oxo-cyclohexanecarboxylic acid ethyl ester 
• 1292278-44-4 ethyl 4-hydroxy-1-(2-methoxyethyl)cyclohexanecarboxylate 
• 1292274-40-8 (5α,8β)-8-hydroxy-2-(4-trifluoromethoxy-phenyl)-2-aza-spiro[4.5]decan-1-one 

Relevant academic research and scientific papers

NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES

The present invention relates to compounds of formula (I) as well as pharmaceutically acceptable salts thereof. The are useful as HSL inhibitors and may, for example, be used in treatment of diabetes, metabolic syndrome, dyslipidemia, atherosclerosis, and obesity.

SPIRO-CONDENSED CYCLOHEXANE DERIVATIVES AS HSL INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES

Compounds of formula (I) as well as pharmaceutically acceptable salts thereof can be used in the form of pharmaceutical compositions as HSL inhibitors for the treatment of diabetes, wherein R1,R2, R3, Ca and Cb have the significance given in claim 1.